Literature DB >> 27257176

mTOR signaling: new networks for ALL.

David A Fruman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27257176      PMCID： PMC4891950          DOI： 10.1182/blood-2016-03-703199

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.

Authors:  Naval Daver; Yanis Boumber; Hagop Kantarjian; Farhad Ravandi; Jorge Cortes; Michael E Rytting; Jitesh D Kawedia; Jordan Basnett; Kirk S Culotta; Zhihong Zeng; Hongbo Lu; Mary Ann Richie; Rebecca Garris; Lianchun Xiao; Wenbin Liu; Keith A Baggerly; Elias Jabbour; Susan O'Brien; Jan Burger; Linda J Bendall; Deborah Thomas; Marina Konopleva
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

2.  Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells.

Authors:  Abdelkader Essafi; Silvia Fernández de Mattos; Yasmin A M Hassen; Inês Soeiro; Ghulam J Mufti; N Shaun B Thomas; René H Medema; Eric W-F Lam
Journal:  Oncogene       Date:  2005-03-31       Impact factor: 9.867

3.  4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.

Authors:  Seongseok Yun; Nicole D Vincelette; Katherine L B Knorr; Luciana L Almada; Paula A Schneider; Kevin L Peterson; Karen S Flatten; Haiming Dai; Keith W Pratz; Allan D Hess; B Douglas Smith; Judith E Karp; Andrea E Wahner Hendrickson; Martin E Fernandez-Zapico; Scott H Kaufmann
Journal:  Blood       Date:  2016-02-25       Impact factor: 22.113

4.  Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E.

Authors:  Andrew C Hsieh; Maria Costa; Ornella Zollo; Cole Davis; Morris E Feldman; Joseph R Testa; Oded Meyuhas; Kevan M Shokat; Davide Ruggero
Journal:  Cancer Cell       Date:  2010-03-16       Impact factor: 31.743

Review 5.  Target of rapamycin signaling in leukemia and lymphoma.

Authors:  Collin Vu; David A Fruman
Journal:  Clin Cancer Res       Date:  2010-09-08       Impact factor: 12.531

6.  PUMA and BIM are required for oncogene inactivation-induced apoptosis.

Authors:  Gregory R Bean; Yogesh Tengarai Ganesan; Yiyu Dong; Shugaku Takeda; Han Liu; Po M Chan; Yafen Huang; Lewis A Chodosh; Gerard P Zambetti; James J-D Hsieh; Emily H-Y Cheng
Journal:  Sci Signal       Date:  2013-03-26       Impact factor: 8.192

7.  Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.

Authors:  Matthew R Janes; Jose J Limon; Lomon So; Jing Chen; Raymond J Lim; Melissa A Chavez; Collin Vu; Michael B Lilly; Sharmila Mallya; S Tiong Ong; Marina Konopleva; Michael B Martin; Pingda Ren; Yi Liu; Christian Rommel; David A Fruman
Journal:  Nat Med       Date:  2010-01-13       Impact factor: 53.440

8.  mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells.

Authors:  Brandon R Beagle; Duc M Nguyen; Sharmila Mallya; Sarah S Tang; Mengrou Lu; Zhihong Zeng; Marina Konopleva; Thanh-Trang Vo; David A Fruman
Journal:  Oncotarget       Date:  2015-02-10

9.  Mammalian target of rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia (ALL).

Authors:  Karolina Nemes; Anna Sebestyén; Agnes Márk; Melinda Hajdu; István Kenessey; Tamás Sticz; Eszter Nagy; Gábor Barna; Zsófia Váradi; Gábor Kovács; László Kopper; Monika Csóka
Journal:  PLoS One       Date:  2013-04-03       Impact factor: 3.240

10.  mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio.

Authors:  Tommy Alain; Nahum Sonenberg; Ivan Topisirovic
Journal:  Oncotarget       Date:  2012-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.